The Proteasome, Protein Aggregation, and Neurodegeneration
Reference223 articles.
1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, et al. 2000. Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239–252.
2. Adams, J. 2003. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 8: 307–315.
3. Aki M, Shimbara N, Takashina M, Akiyama K, Kagawa S, et al. 1994. Interferon-γ induces different subunit organizations and functional diversity of proteasomes. J Biochem 115: 257–269.
4. Ancolio K, Alves da Costa C, Ueda K, Checler F. 2000. α-synuclein and the Parkinson's disease-related mutant Ala53Thr-α-synuclein do not undergo proteasomal degradation in HEK293 and neuronal cells. Neurosci Lett 285: 79–82.
5. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, et al. 2003. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci U S A 100: 5950–5955.